CL2018000422A1 - Diacuerpos monovalentes biespecíficos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos - Google Patents
Diacuerpos monovalentes biespecíficos que son capaces de unirse a b7-h3 y cd3, y usos de los mismosInfo
- Publication number
- CL2018000422A1 CL2018000422A1 CL2018000422A CL2018000422A CL2018000422A1 CL 2018000422 A1 CL2018000422 A1 CL 2018000422A1 CL 2018000422 A CL2018000422 A CL 2018000422A CL 2018000422 A CL2018000422 A CL 2018000422A CL 2018000422 A1 CL2018000422 A1 CL 2018000422A1
- Authority
- CL
- Chile
- Prior art keywords
- bispecific monovalent
- diabodies
- binding
- monovalent diabodies
- directed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se dirige a diacuerpos monovalentes biespecíficos DE B7-H3 x CD3, y particularmente, a diacuerpos Fc monovalentes biespecíficos de B7-H3 x CD3, que son capaces de unirse de forma simultánea a B7-H3 y CD3. La invención también se dirige a composiciones farmacéuticas que contienen tales diacuerpos Fc monovalentes biespecíficos. La invención se dirige adicionalmente a métodos para el uso de tales diacuerpos en el tratamiento de cáncer y otras enfermedades y padecimientos
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562206051P | 2015-08-17 | 2015-08-17 | |
US201662280318P | 2016-01-19 | 2016-01-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2018000422A1 true CL2018000422A1 (es) | 2018-08-10 |
Family
ID=58051498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2018000422A CL2018000422A1 (es) | 2015-08-17 | 2018-02-15 | Diacuerpos monovalentes biespecíficos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos |
Country Status (21)
Country | Link |
---|---|
US (1) | US20190002563A1 (es) |
EP (1) | EP3337507A4 (es) |
JP (1) | JP2018523686A (es) |
KR (1) | KR20180038045A (es) |
CN (1) | CN107921130A (es) |
AU (1) | AU2016307955A1 (es) |
CA (1) | CA2995709A1 (es) |
CL (1) | CL2018000422A1 (es) |
CO (1) | CO2018001485A2 (es) |
CR (1) | CR20180105A (es) |
EA (1) | EA201890443A1 (es) |
EC (1) | ECSP18011248A (es) |
HK (1) | HK1249423A1 (es) |
IL (1) | IL257562A (es) |
MA (1) | MA42665A (es) |
MX (1) | MX2018001954A (es) |
PE (1) | PE20181066A1 (es) |
PH (1) | PH12018500363A1 (es) |
TW (1) | TW201718652A (es) |
WO (1) | WO2017030926A1 (es) |
ZA (1) | ZA201800955B (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ726514A (en) | 2014-05-29 | 2019-01-25 | Macrogenics Inc | Tri-specific binding molecules and methods of use thereof |
EP3197917B1 (en) * | 2014-09-26 | 2022-10-12 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof |
TWI758267B (zh) | 2015-12-14 | 2022-03-21 | 美商宏觀基因股份有限公司 | 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法 |
US11459394B2 (en) | 2017-02-24 | 2022-10-04 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
MY200973A (en) | 2017-04-11 | 2024-01-26 | Inhibrx Inc | Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same |
BR112020004543A2 (pt) * | 2017-09-08 | 2020-09-08 | Maverick Therapeutics, Inc. | proteínas de ligação ativadas condicionalmente restritas |
CN109939231A (zh) * | 2017-12-21 | 2019-06-28 | 张曼 | 关于cd3×b7h3双特异性抗体定向杀伤膀胱癌细胞t24的应用 |
CN109939126A (zh) * | 2017-12-21 | 2019-06-28 | 张曼 | Cd3×b7h3双特异抗体定向杀伤耐阿霉素膀胱癌细胞pumc-91/adm的应用 |
CN109939232A (zh) * | 2017-12-21 | 2019-06-28 | 张曼 | 关于cd3×b7h3双特异性抗体定向杀伤膀胱癌细胞pumc-91的应用 |
CN109939230A (zh) * | 2017-12-21 | 2019-06-28 | 张曼 | 关于cd3×b7h3双特异性抗体定向杀伤耐顺铂膀胱癌细胞t24/ddp的应用 |
CN109971711A (zh) * | 2017-12-27 | 2019-07-05 | 张曼 | 关于cd3×b7h3双特异性抗体定向杀伤人膀胱癌细胞的应用 |
SG11202007572VA (en) * | 2018-02-15 | 2020-09-29 | Macrogenics Inc | Variant cd3-binding domains and their use in combination therapies for the treatment of disease |
EP3773913A1 (en) | 2018-04-11 | 2021-02-17 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses |
TW202016151A (zh) * | 2018-06-09 | 2020-05-01 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
CN112789294A (zh) | 2018-07-24 | 2021-05-11 | 印希比股份有限公司 | 含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法 |
CN109762068A (zh) * | 2018-08-09 | 2019-05-17 | 源道隆(苏州)医学科技有限公司 | 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用 |
EP3864044A1 (en) | 2018-10-11 | 2021-08-18 | Inhibrx, Inc. | B7h3 single domain antibodies and therapeutic compositions thereof |
JP7453219B2 (ja) | 2018-10-11 | 2024-03-19 | インヒブリックス, インコーポレイテッド | Pd-1単一ドメイン抗体およびその治療用組成物 |
CN112955471B (zh) * | 2018-12-07 | 2022-11-22 | 江苏恒瑞医药股份有限公司 | Cd3抗体及其药物用途 |
TW202033218A (zh) * | 2018-12-07 | 2020-09-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 多特異性蛋白分子 |
KR20210006637A (ko) * | 2019-07-09 | 2021-01-19 | 주식회사 와이바이오로직스 | B7-h3(cd276)에 특이적으로 결합하는 항체 및 그의 용도 |
CN111454357B (zh) * | 2019-08-14 | 2022-03-15 | 康诺亚生物医药科技(成都)有限公司 | 一种含有抗体的肿瘤治疗剂的开发和应用 |
EP3822288A1 (en) * | 2019-11-18 | 2021-05-19 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof |
MX2022009306A (es) | 2020-01-29 | 2022-09-26 | Inhibrx Inc | Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos. |
WO2022232392A2 (en) * | 2021-04-28 | 2022-11-03 | Lyvgen Biopharma Holdings Limited | Bi-specific antibodies comprising anti-b7h3 binding molecules |
US20230151095A1 (en) | 2021-11-12 | 2023-05-18 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and nkg2d |
CN114539420B (zh) * | 2022-01-20 | 2024-05-17 | 荣昌生物制药(烟台)股份有限公司 | 抗b7-h3单克隆抗体、抗b7-h3×cd3双特异性抗体、制备方法及其应用 |
CN117903311A (zh) * | 2024-03-20 | 2024-04-19 | 湖南卓润生物科技有限公司 | sST2特异性结合蛋白及其制备方法和应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9150656B2 (en) * | 2010-03-04 | 2015-10-06 | Macrogenics, Inc. | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof |
RS58765B1 (sr) * | 2011-05-21 | 2019-06-28 | Macrogenics Inc | Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3 |
US10851178B2 (en) * | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
US9487587B2 (en) * | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
US20140302037A1 (en) * | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
UA116479C2 (uk) * | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ |
EP2839842A1 (en) * | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
MX2018004177A (es) * | 2015-10-08 | 2018-09-11 | Macrogenics Inc | Terapia de combinacion para el tratamiento de cancer. |
-
2016
- 2016-08-12 AU AU2016307955A patent/AU2016307955A1/en not_active Abandoned
- 2016-08-12 MA MA042665A patent/MA42665A/fr unknown
- 2016-08-12 EA EA201890443A patent/EA201890443A1/ru unknown
- 2016-08-12 MX MX2018001954A patent/MX2018001954A/es unknown
- 2016-08-12 CN CN201680048182.7A patent/CN107921130A/zh active Pending
- 2016-08-12 JP JP2018508741A patent/JP2018523686A/ja active Pending
- 2016-08-12 CA CA2995709A patent/CA2995709A1/en not_active Abandoned
- 2016-08-12 WO PCT/US2016/046680 patent/WO2017030926A1/en active Application Filing
- 2016-08-12 CR CR20180105A patent/CR20180105A/es unknown
- 2016-08-12 KR KR1020187007443A patent/KR20180038045A/ko unknown
- 2016-08-12 PE PE2018000249A patent/PE20181066A1/es unknown
- 2016-08-12 EP EP16837560.8A patent/EP3337507A4/en not_active Withdrawn
- 2016-08-12 US US15/752,367 patent/US20190002563A1/en not_active Abandoned
- 2016-08-16 TW TW105126154A patent/TW201718652A/zh unknown
-
2018
- 2018-02-13 ZA ZA2018/00955A patent/ZA201800955B/en unknown
- 2018-02-15 PH PH12018500363A patent/PH12018500363A1/en unknown
- 2018-02-15 CO CONC2018/0001485A patent/CO2018001485A2/es unknown
- 2018-02-15 EC ECIEPI201811248A patent/ECSP18011248A/es unknown
- 2018-02-15 CL CL2018000422A patent/CL2018000422A1/es unknown
- 2018-02-15 IL IL257562A patent/IL257562A/en unknown
- 2018-07-11 HK HK18109035.8A patent/HK1249423A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CO2018001485A2 (es) | 2018-07-10 |
EP3337507A4 (en) | 2019-04-24 |
IL257562A (en) | 2018-04-30 |
CN107921130A (zh) | 2018-04-17 |
KR20180038045A (ko) | 2018-04-13 |
HK1249423A1 (zh) | 2018-11-02 |
MA42665A (fr) | 2018-06-27 |
TW201718652A (zh) | 2017-06-01 |
MX2018001954A (es) | 2018-11-09 |
ZA201800955B (en) | 2018-11-28 |
CR20180105A (es) | 2018-06-12 |
US20190002563A1 (en) | 2019-01-03 |
AU2016307955A1 (en) | 2018-03-08 |
EP3337507A1 (en) | 2018-06-27 |
JP2018523686A (ja) | 2018-08-23 |
PH12018500363A1 (en) | 2018-09-10 |
PE20181066A1 (es) | 2018-07-04 |
ECSP18011248A (es) | 2018-04-30 |
EA201890443A1 (ru) | 2018-09-28 |
CA2995709A1 (en) | 2017-02-23 |
WO2017030926A1 (en) | 2017-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018000422A1 (es) | Diacuerpos monovalentes biespecíficos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos | |
CO2018001149A2 (es) | Anticuerpos monoclonales contra bcma | |
CL2018001545A1 (es) | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas | |
CL2018001512A1 (es) | Anticuerpos anti-cd73 humanizados. | |
CO2018003452A2 (es) | Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso | |
CO2017000016A2 (es) | Diacuerpos heterodiméricos biespecíficos capaces de unirse en forma específica a un epítopo de p-cadherina y a un epítopo de cd3 que comprende una primera cadena polipeptídica y una segunda cadena polipeptídica y composiciones farmacéuticas de los mismos | |
CL2017001459A1 (es) | Biarilo compuestos útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología | |
CR20150502A (es) | Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización | |
DOP2017000083A (es) | Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3, y usos de los mismos | |
CO2017006740A2 (es) | Anticuerpos anti–cd79b | |
CL2020003028A1 (es) | Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos. | |
CL2017000311A1 (es) | Anticuerpos anti-lag3 y fragmentos de unión a antígeno | |
AR109625A1 (es) | Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas | |
CU20160101A7 (es) | Inmunoglobulina con fab en tándem | |
CR20160108A (es) | Diacuerpos monovalentes biespecificos que son capaces de unir a cd123 y cd3 y el uso de los mismos | |
BR112018004733A2 (pt) | anticorpos do receptor de transferrina humana/ a-beta anti-humana biespecíficos e métodos de uso | |
GT201700131A (es) | Composiciones y métodos para anticuerpos dirigidos a bmp6 | |
EA201791310A1 (ru) | Химерные антигенные рецепторы к bcma | |
UY36289A (es) | ANTICUERPOS MONOCLONALES QUE ENLAZAN INMUNOESPECIFICAMENTE A CD123 y COMPOSICIONES QUE LOS CONTIENEN | |
SV2017005486A (es) | Anticuerpos a tau y usos de los mismos | |
ECSP16075416A (es) | Anticuerpos de il-21 | |
CL2016001753A1 (es) | Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer | |
CO2017000950A2 (es) | Compuestos que comprenden oligonucleótidos modificados dirigidos a mir-103 y/o mir-107 para trastornos metabólicos | |
CL2019002735A1 (es) | Anticuerpos que se unen a steap-1. | |
DOP2016000211A (es) | Pirazinas moduladoras de gpr6 |